This is one of the most-confused points in the GLP-1 space. Telehealth marketing copy often blurs the line, but the regulatory facts are clear.
What IS FDA-approved
Semaglutide as a molecule is FDA-approved in two specific drug products: Wegovy (for chronic weight management) and Ozempic (for type 2 diabetes). Both are manufactured by Novo Nordisk. They went through standard FDA approval pathways with randomized trials, manufacturing inspection, and post-market surveillance.
What is NOT FDA-approved
Compounded semaglutide products produced by 503A or 503B pharmacies are NOT FDA-approved drugs, even when they contain the same semaglutide molecule. They have not gone through randomized trials specific to the compounded formulation. Dose accuracy is not federally audited. Manufacturing is overseen but inconsistently — 503A is regulated by state boards of pharmacy; 503B has more FDA oversight but still no drug-approval status.
Why the confusion exists
Compounding pharmacies are legally allowed to produce semaglutide formulations under specific conditions — primarily when FDA has declared the branded version in "shortage" (as semaglutide was 2022-2024). Some compounders use this allowance to market broadly, blurring the language between "FDA-approved" and "contains an FDA-approved active ingredient." These are not the same thing.
Always ask: is this drug FDA-approved (yes/no), or is the molecule FDA-approved in a different product (yes/no)? They are different questions.